NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


DNA damage response;
Precision Medicine;
rational drug combinations

Recruitment Keyword(s)



Urothelial Carcinoma;
Non-Small Cell Lung Cancer;
Penile Cancer;
Malignant Pleural Mesothelioma;
Biliary Tract Cancer

Investigational Drug(s)

BAY 1895344

Investigational Device(s)



Drug: gemcitabine
Drug: cisplatin
Drug: BAY 1895344

Supporting Site

National Cancer Institute


In 2019, about 600,000 people died from cancer in the U.S. About 17,760 of those deaths were caused by bladder cancer. Researchers want to find new treatments for solid tumors.


To test the safety of BAY 1895344 in combination with cisplatin or cisplatin plus gemcitabine in people with advanced solid tumors or urothelial carcinoma.


Adults aged 18 or older who have advanced solid tumors that can be treated with cisplatin or cisplatin plus gemcitabine.


Participants will be screened with a review of their medical records. They will have a physical exam. They will have heart and blood tests. They will have imaging scans to measure their tumors.

Participants will be put into groups. Some groups will get 2 drugs (cisplatin and BAY 1895344), and some will get 3 (cisplatin, gemcitabine, and BAY 1895344). Treatment will be given in 3-week cycles, for up to 6 cycles. They will get cisplatin or cisplatin plus gemcitabine through a vein in their arm on 1 or 2 days of each cycle. They will take the study drug by mouth twice a day on 2 days of each cycle.

Participants will have study visits during each cycle. At visits, they may repeat some screening tests. They may have frequent blood draws. Some blood samples will be used for genetic tests and research.

Participants will be followed by their doctor for 30 days after treatment ends. They will have follow-up visits every 3 months. They may have these visits over the phone. If their cancer gets worse, follow-up will stop.

--Back to Top--



-Histologically-confirmed advanced solid tumor with measurable disease by RECIST v1.1 criteria, for which cisplatin-based therapy would be considered appropriate, including:



--Penile cancer

--Malignant pleural mesothelioma

--Small cell lung cancer

--Biliary tract cancer

--Esophageal and gastric cancers

--Ovarian cancer

--Endometrial cancer

--Cervical cancer

--Head and neck cancer

--Triple-negative breast cancer (Her2/neu-negative, ER/PR-negative breast cancer)

-For the expansion cohort of the triplet combination at MTD/RP2D only:

--Patients with histologically confirmed advanced or unresectable urothelial carcinoma are eligible.

--The histology should be predominantly urothelial (>=50% of sample evaluated contains urothelial histology).

-Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 in combination with gemcitabine and cisplatin in patients <18 years of age, children are excluded from this study.

-ECOG performance status <=2 (Karnofsky >=60%).

- Availability of archival FFPE tissue.

- Prior cisplatin exposure of < 300 mg/m^2. Patients with prior cisplatin treatment must have 19

received last cisplatin treatment > 6 months prior to enrollment.

- Prior treatment with PARP inhibitors is permitted (such as olaparib, rucaparib, or other experimental inhibitors of PARP administered in a clinical trial).

- Prior immune checkpoint inhibitor therapy is permitted (including anti-PD-1, anti-PD-L1 therapy, such as pembrolizumab, nivolumab, avelumab, durvalumab, atezolizumab, or anti-CTLA4 therapy such as ipilimumab, or other experimental immune checkpoint pathway inhibitors administered in a clinical trial).

- Patients must have adequate organ and marrow function as defined below:

-leukocytes >=3,000/mcL

-hemoglobin >=9g/dL

-neutrophil count >=1,500/mcL

-platelets >=100,000/mcL

-total bilirubin <= 2 mg/dL

-AST(SGOT)/ALT(SGPT) <=3 (SqrRoot) institutional ULN

-creatinine clearance >= 40 mL/min


-glomerular filtration rate (GFR) >=60 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2

- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.

- Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy; patients with stable brain metastases that are asymptomatic and on a stable dose of steroids are also considered eligible.

- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.

- The effects of BAY 1895344, cisplatin, and gemcitabine on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 administration.

- Ability to understand and the willingness to sign a written informed consent document.


- Life expectancy < 6 weeks by investigator assessment.

- Other active malignancy requiring treatment, except for cutaneous malignancies that require resection such as squamous cell carcinoma, basal cell carcinoma, or cutaneous melanoma, and except for prostate cancer if only on androgen deprivation therapy.

- Significant peripheral neuropathy (<Grade 2 by CTCAE).

- Sensorineural hearing loss (<Grade 2 by CTCAE).

- Must NOT have had prior treatment with ATR inhibitor (prior BAY1895344 or other investigational ATR inhibitors), or current treatment with any other investigational agents.

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Patients who have targeted therapies (such as PARP inhibitors) within 2 weeks prior to entering the study.

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344 or other agents used in study.

- Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. Appendix D should be presented to the patient.

- Patients with uncontrolled intercurrent illness.

- Patients with psychiatric illness/social situations that would limit compliance with study requirements.

- Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor, cisplatin, and gemcitabine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Naoko Takebe, M.D.
National Cancer Institute (NCI)
(240) 541-4515

Mary Jane Ong
National Cancer Institute (NCI)
BG 10 RM 8D53
(240) 858-3296

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--